Cell-cycle fate-monitoring distinguishes individual chemosensitive and chemoresistant cancer cells in drug-treated heterogeneous populations demonstrated by real-time FUCCI imaging

被引:23
作者
Miwa, Shinji [1 ,2 ,3 ]
Yano, Shuya [1 ,2 ,4 ]
Kimura, Hiroaki [3 ]
Yamamoto, Mako [1 ,2 ]
Toneri, Makoto [1 ,2 ]
Matsumoto, Yasunori [1 ,2 ]
Uehara, Fuminari [1 ,2 ]
Hiroshima, Yukihiko [1 ,2 ]
Murakami, Takashi [1 ,2 ]
Hayashi, Katsuhiro [3 ]
Yamamoto, Norio [3 ]
Bouvet, Michael [2 ]
Fujiwara, Toshiyoshi [4 ]
Tsuchiya, Hiroyuki [3 ]
Hoffman, Robert M. [1 ,2 ]
机构
[1] AntiCancer Inc, San Diego, CA 92111 USA
[2] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA
[3] Kanazawa Univ, Grad Sch Med Sci, Dept Orthoped Surg, Kanazawa, Ishikawa, Japan
[4] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Surg, Div Surg Oncol, Okayama 7008530, Japan
关键词
cancer; cell cycle; chemoresistance; chemosensitivity; cisplatinum; doxorubicin; FUCCI; GFP; RFP; HeLa; time-lapse imaging; tumor heterogeneity; THYMIDYLATE SYNTHASE INHIBITOR; TUMOR HETEROGENEITY; GROWTH-INHIBITION; ASCITES TUMORS; DNA-DAMAGE; STEM-CELL; THERAPY; ARREST; P53; CHEMOTHERAPY;
D O I
10.4161/15384101.2014.991604
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Essentially every population of cancer cells within a tumor is heterogeneous, especially with regard to chemosensitivity and resistance. In the present study, we utilized the fluorescence ubiquitination-based cell cycle indicator (FUCCI) imaging system to investigate the correlation between cell-cycle behavior and apoptosis after treatment of cancer cells with chemotherapeutic drugs. HeLa cells expressing FUCCI were treated with doxorubicin (DOX) (5M) or cisplatinum (CDDP) (5M) for 3h. Cell-cycle progression and apoptosis were monitored by time-lapse FUCCI imaging for 72h. Time-lapse FUCCI imaging demonstrated that both DOX and CDDP could induce cell cycle arrest in S/G(2)/M in almost all the cells, but a subpopulation of the cells could escape the block and undergo mitosis. The subpopulation which went through mitosis subsequently underwent apoptosis, while the cells arrested in S/G(2)/M survived. The present results demonstrate that chemoresistant cells can be readily identified in a heterogeneous population of cancer cells by S/G(2)/M arrest, which can serve in future studies as a visible target for novel agents that kill cell-cycle-arrested cells.
引用
收藏
页码:621 / 629
页数:9
相关论文
共 39 条
[1]   The challenges posed by cancer heterogeneity [J].
Bhatia, Sangeeta ;
Frangioni, John V. ;
Hoffman, Robert M. ;
Iafrate, A. John ;
Polyak, Kornelia .
NATURE BIOTECHNOLOGY, 2012, 30 (07) :604-610
[2]   Targeting the absence and therapeutic engineering for cancer therapy [J].
Blagosklonny, Mikhail V. .
CELL CYCLE, 2008, 7 (10) :1307-1312
[3]   Cancer stem cell and cancer stemloids [J].
Blagosklonny, Mikhail V. .
CANCER BIOLOGY & THERAPY, 2007, 6 (11) :1684-1690
[4]   Mitotic arrest and cell - Fate why and how mitotic inhibition of transcription drives mutually exclusive events [J].
Blagosklonny, Mikhail V. .
CELL CYCLE, 2007, 6 (01) :70-74
[5]   The power of chemotherapeutic engineering Arresting cell cycle and suppressing senescence to protect from mitotic inhibitors [J].
Blagosklonny, Mikhail V. .
CELL CYCLE, 2011, 10 (14) :2295-2298
[6]   Target for cancer therapy: proliferating cells or stem cells [J].
Blagosklonny, MV .
LEUKEMIA, 2006, 20 (03) :385-391
[7]   Teratogens as anti-cancer drugs [J].
Blagosklonny, MV .
CELL CYCLE, 2005, 4 (11) :1518-1521
[8]   How cancer could be cured by 2015 [J].
Blagosklonny, MV .
CELL CYCLE, 2005, 4 (02) :269-278
[9]   Matching targets for selective cancer therapy [J].
Blagosklonny, MV .
DRUG DISCOVERY TODAY, 2003, 8 (24) :1104-1107
[10]   Tissue-selective therapy of cancer [J].
Blagosklonny, MV .
BRITISH JOURNAL OF CANCER, 2003, 89 (07) :1147-1151